Reactome | Drug resistance of KIT mutants
Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib | Cell & Bioscience | Full Text
Current Oncology | Free Full-Text | Precision Oncology in Gastrointestinal Stromal Tumors
Mechanisms of Disease Persistence in Gastrointestinal Stromal Tumors - The Life Raft Group
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders - ScienceDirect
Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors - Damien Kee, John R. Zalcberg, 2012
Diapositiva 1
GIST Mutations - Types of GIST Cancer Gene Mutations & Testing | The Life Raft Group
IJMS | Free Full-Text | Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
![PDF] The SCF/c-KIT system and imatinib actions in prostate cancer: a cross-talk with RGN? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/52568705464442ace5fec86bca4a1528e3281c4b/70-FigureV-1.png "PDF] The SCF/c-KIT system and imatinib actions in prostate cancer: a cross-talk with RGN? | Semantic Scholar")
PDF] The SCF/c-KIT system and imatinib actions in prostate cancer: a cross-talk with RGN? | Semantic Scholar
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients | PNAS
Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. - Abstract - Europe PMC
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval | Future Oncology
The KIT receptor tyrosine kinase. (A) C-KIT mutations occur in 80 –90%... | Download Scientific Diagram
Using Imatinib for Adjuvant Treatment after Resection of Kit-positive GIST - The ASCO Post
JCI - Structural reengineering of imatinib to decrease cardiac risk in cancer therapy
Presentazione standard di PowerPoint
Frontiers | An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
c-KIT and PDGFRA mutation detection for GIST – آزمایشگاه پرتولب
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours | British Journal of Cancer
Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors | SpringerLink
Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis | Scientific Reports
Imatinib Mesylate — A New Oral Targeted Therapy | NEJM
Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity | Bentham Science
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations - The Lancet Oncology
